Business
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery
SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule at the Endocrine Society’s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA. Details of the presentations are as follows: Abstract Title: Oral Delivery of a Bispecific GLP
About this update from Rani Therapeutics Holdings, Inc.
[{"type":"image","alt":"Rani Therapeutics, LLC","displaySize":"","headline":null,"caption":"Rani Therapeutics, LLC","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/eedd36d474bbaf8ede890d5712b0f73a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XWNAoYI1bIyf8QCPVkOpHw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/eedd36d474bbaf8ede890d5712b0f73a","width":300,"height":150}},"lazy":false},{"type":"text","content":"SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule at the Endocrine Society’s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA.","length":405,"tagName":"p"},{"type":"text","content":"Details of the presentations are as follows:","length":44,"tagName":"p"},{"type":"text","content":"Abstract Title: Oral Delivery of a Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114) Achieves Bioequivalence to Subcutaneous Injection in Canines","length":172,"tagName":"p"},{"type":"text","content":"Session Type: Poster Presentation","length":33,"tagName":"p"},{"type":"text","content":"Session Title: Adipose Tissue, Appetite, and Obesity: From Breakthroughs to Real-World Challenges: Navigating Weight Loss, Regain, and Therapeutic Advances II","length":158,"tagName":"p"},{"type":"text","content":"Session Date & Time: July 14, 2025 from 12:00 PM to 1:30 PM PT","length":66,"tagName":"p"},{"type":"text","content":"Poster Number: MON-691","length":22,"tagName":"p"},{"type":"text","content":"Presenting Author: Anvesh Dasari, PhD","length":37,"tagName":"p"},{"type":"text","content":"The abstract presented at ENDO 2025 is available on the Endocrine Society website.","length":87,"tagName":"p"},{"type":"text","content":"About Rani Therapeutics","length":23,"tagName":"p"},{"type":"text","content":"Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, propriet...